Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Monday Oct 18, 2021
Monday Oct 18, 2021
touchPANEL DISCUSSION for touchONCOLOGY
Listen to leading experts discuss evolving treatment options for patients with EGFR-mutant NSCLC, and the rationale for biomarker testing in both early-stage and metastatic disease to determine best treatment approaches, taking in recently presented data from the World Lung Cancer Congress and ESMO Congress 2021.
The experts
- Dr Pasi Jӓnne, Dana-Farber Cancer Institute, Boston, MA, USA
- Dr Thanyanan Reungwetwattana, Ramathibodi Hospital, Bangkok, Thailand
- Dr Neal Navani, University College London, London, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/deciphering-data-egfr-mutant-nsclc/
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.